10-Q: Amylyx Pharmaceuticals Reports Q2 2026 Results

Amylyx Pharmaceuticals details Q2 2026 financial performance, highlighting increased R&D and SG&A expenses, while advancing its pipeline candidates avexitide and AMX0035.

Summary

• Amylyx Pharmaceuticals reported a net loss of $43.4 million for the three months ended June 30, 2026, compared to a net loss of $41.4 million for the same period in 2025.
• Total operating expenses increased by 7% to $45.7 million for Q2 2026, driven by a 40% increase in Selling, General, and Administrative (SG&A) expenses.
• Research and Development (R&D) expenses decreased by 13% to $23.8 million, primarily due to the discontinuation of AMX0035 for PSP, partially offset by increased costs for avexitide's Phase 3 LUCIDITY trial.
• For the six months ended June 30, 2026, the net loss was $84.7 million, an increase from $77.4 million in the prior year period.
• Total operating expenses for the first six months of 2026 rose by 11% to $89.5 million.
• The company reported cash, cash equivalents, and marketable securities of $250.8 million as of June 30, 2026, and expects this to fund operations into 2028.
• The company has entered into a settlement in principle for a class action lawsuit for $6.5 million.
• Amylyx is advancing its pipeline with avexitide for PBH and AMX0035 for Wolfram syndrome, with topline data for the avexitide Phase 3 trial expected in Q3 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued net losses, increased operating expenses, and the discontinuation of RELYVRIO/ALBRIOZA, despite progress in pipeline development.

Positives

• Continued progress in advancing key pipeline candidates, avexitide (for PBH) and AMX0035 (for Wolfram syndrome).
• Topline data for the Phase 3 LUCIDITY trial of avexitide is expected in the third quarter of 2026, with a potential commercial launch in 2027.
• The company believes its existing cash, cash equivalents, and marketable securities of $250.8 million as of June 30, 2026, are sufficient to fund operations into 2028.
• Avexitide has received Breakthrough Therapy Designation from the FDA for both PBH and congenital HI.
• AMX0035 has shown positive results in the Phase 2 HELIOS trial for Wolfram syndrome, with sustained improvements observed.
• AMX0114 has received FDA Fast Track Designation for the potential treatment of ALS.

Negatives

• Net loss of $43.4 million for the three months ended June 30, 2026, and $84.7 million for the six months ended June 30, 2026.
• Total operating expenses increased to $45.7 million for Q2 2026 and $89.5 million for the first six months of 2026.
• SG&A expenses increased significantly by 40% for Q2 2026 and 22% for the first six months of 2026.
• The company voluntarily discontinued marketing authorizations for RELYVRIO and ALBRIOZA for ALS.
• The company has an accumulated deficit of $836.1 million as of June 30, 2026.
• The company expects to continue generating operating losses for the foreseeable future.

Risks

• The company depends heavily on the success of avexitide and AMX0035; failure to obtain regulatory approvals or commercialize them could materially harm the business.
• The company expects to generate significant losses for the foreseeable future and may require substantial additional funding.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or unsatisfactory performance.
• The markets for its product candidates may be smaller than anticipated.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's intellectual property protection may not be sufficient.
• The company is subject to ongoing legal proceedings, including a class action lawsuit and derivative complaints.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund its operations into 2028. It expects to continue generating operating losses for the foreseeable future and anticipates increased expenses as it advances its development programs. Topline data for the avexitide Phase 3 LUCIDITY trial is expected in Q3 2026, with a potential commercial launch in 2027.

Management Comments

• We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality.
• We continue to expect to announce topline data in the third quarter of 2026, and, if approved, a commercial launch in 2027.
• We continue to work with the FDA on a Phase 3 trial in Wolfram syndrome.

Industry Context

StockSavvy.ai notes that Amylyx Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector, focusing on neurodegenerative and endocrine diseases. The company's strategy involves advancing multiple product candidates through clinical development, a common approach in the industry. The recent discontinuation of RELYVRIO/ALBRIOZA for ALS highlights the inherent risks in drug development and commercialization, a challenge faced by many peers.

Comparison to Industry Standards

• Amylyx's R&D expenses as a percentage of total operating expenses (approximately 52% for the six months ended June 30, 2026) are in line with industry averages for clinical-stage biopharmaceutical companies, reflecting a strong focus on pipeline advancement.
• The company's net loss per share of $(0.76) for the six months ended June 30, 2026, is also typical for companies at this stage of development, where significant investment in R&D precedes revenue generation.
• The cash burn rate, while substantial, is being managed with a stated runway into 2028, which is a critical metric for investors assessing the financial health and operational sustainability of such companies.

Legal Proceedings

• A putative class action lawsuit (Shih v. Amylyx Pharmaceuticals, Inc.) alleging violations of Section 10(b) and Rule 10b-5 of the Exchange Act related to commercial results and prospects for RELYVRIO. Parties have reached an agreement in principle to settle for $6.5 million, with a hearing scheduled for September 10, 2026.
• Two derivative complaints (Jones v. Cohen, et al. and Hassine v. Cohen, et al.) filed against current and former directors and officers, mirroring allegations of the Shih Complaint and asserting claims for violations of the Exchange Act, breach of fiduciary duty, insider trading, and unjust enrichment. Parties are negotiating a settlement term sheet.

Stakeholder Impact

• Shareholders may experience continued dilution if the company needs to raise additional capital through equity offerings.
• Employees may face uncertainty due to the company's ongoing losses and the need for efficient cash utilization.
• Patients with PBH and Wolfram syndrome may benefit from the continued development of avexitide and AMX0035, respectively, with potential commercial launches in the coming years.
• Suppliers and contract manufacturers may experience shifts in demand following the discontinuation of RELYVRIO/ALBRIOZA.

Next Steps

• Announce topline data from the Phase 3 LUCIDITY clinical trial for avexitide in PBH in the third quarter of 2026.
• Prepare for a potential commercial launch of avexitide in 2027, if approved.
• Continue discussions with the FDA regarding a Phase 3 trial for AMX0035 in Wolfram syndrome.
• Advance IND-enabling studies for AMX0318 with an IND submission targeted for 2027.
• Continue Phase 1 LUMINA clinical trial for AMX0114 in ALS, with Cohort 3 currently enrolling.

Key Dates

Recommendation

Amylyx Pharmaceuticals is a clinical-stage company with promising pipeline candidates, but it continues to incur significant losses and has recently discontinued a key product. While the progress in avexitide and AMX0035 development is positive, the increased operating expenses and the overall financial performance warrant a cautious approach. Investors should monitor the upcoming topline data for the LUCIDITY trial and the company's ability to manage its cash burn and secure future funding.

Keywords

Amylyx Pharmaceuticals, 10-Q Filing, Quarterly Report, Avexitide, AMX0035, PBH, Wolfram Syndrome, ALS